Special Issue

Dermatology: Molecular Mechanisms, Diagnosis and Therapeutic Targets

Message from the Guest Editors

The skin is a unique sensory organ that can experience itch, pain, and other tactile nerve signals. Malfunctions or the dysregulation of skin homeostasis can contribute to a variety of skin diseases, such as psoriasis, atopic dermatitis, melanoma, and autoimmune diseases including vitiligo, alopecia, and scleroderma. Many dermatoses present a long and persistent clinical course and impact patients' quality of life. However, recent advances in pathogenesis analysis have led to new therapeutic approaches, such as specific biologics and other molecularly targeted drugs. Like other areas of medicine, the field of dermatology is now facing a new era of personalized therapies. This Special Issue aims to explore the latest research advances in the etiology, molecular mechanisms, diagnosis, and personalized treatment of dermatological diseases. Both clinical and basic science research will be considered, and researchers are warmly invited to submit original research manuscripts and comments to give readers a deeper understanding of these complex diseases and a fresher perspective on the field.

Guest Editors

Dr. Trinidad Montero-Vilchez

Dermatology Unit, Hospital Universitario Virgen de las Nieves, IBS Granada, 18002 Granada, Spain

Prof. Dr. Salvador Arias-Santiago

Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain

Deadline for manuscript submissions

5 February 2025

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed

mdpi.com/si/192518

Journal of Personalized Medicine
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).